---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-075392"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:21:35.357375+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics receives Nasdaq minimum bid price deficiency notice

## Summary
- Nasdaq notice on Sept 6, 2023, for bid price below $1.00 for 30 consecutive days.
- Company has 180 calendar days until March 4, 2024, to regain compliance.
- To comply, closing bid price must be at least $1.00 for 10 consecutive business days.
- Company may consider options including reverse stock split to regain compliance.
- Delisting not immediate; subject to remaining listing requirements.

## SEC filing metadata
- accession: 0001213900-23-075392
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023075392/0001213900-23-075392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023075392/ea184815-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-075392
- JSON: https://secwatch.observer/filing/0001213900-23-075392.json
- Plain text: https://secwatch.observer/filing/0001213900-23-075392.txt

## Key facts
- Listing & Compliance Notices
  Cadrenal Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 6, 2023, Cadrenal Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”), requiring listed securities to maintain a minimum bid price of $1.00 per share because the Company’s closing bid price for the last 30 consecutive business days was below $1.00 per share. The notification received has no immediate effect on the Company’s continued listing on the Nasdaq Capital Market, subject to the Company’s compliance with the other continued listing requiremen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023075392/0001213900-23-075392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.